Laurus Labs (LAURUSLABS)₹2,454+3.54%Pharmaceuticals
In the Sep 2026 quarter (consolidated), Laurus Labs reported sales of ₹2,198 Cr, up 33.3% from Sep 2025, and net profit of ₹436 Cr, up 124.7% year on year. For the year to Mar 2026, sales were ₹6,795 Cr and net profit ₹890 Cr.
Company filings, consolidated accounts; latest reported quarter Sep 2026
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,191 | 1,436 | 1,193 | 1,220 | 1,412 | 1,716 | 1,565 | 1,649 | 1,773 | 1,807 | 2,020 | 2,198 |
| Expenses | 1,010 | 1,195 | 1,020 | 1,041 | 1,126 | 1,296 | 1,183 | 1,246 | 1,294 | 1,295 | 1,382 | 1,450 |
| Operating Profit | 181 | 241 | 171 | 178 | 285 | 421 | 382 | 403 | 480 | 513 | 638 | 751 |
| OPM % | 15.1% | 17.0% | 14.1% | 15.1% | 20.1% | 24.1% | 24.1% | 24.1% | 27.0% | 28.1% | 32.1% | 34.0% |
| Other Income | 1.99 | 18.94 | 2.99 | 4.98 | 8.98 | 58.79 | 9.97 | 26.92 | 5.98 | 11.96 | 8.97 | 12.96 |
| Interest | 51.08 | 50.05 | 49.04 | 53.08 | 58.10 | 56.03 | 52.10 | 40.05 | 39.04 | 40.02 | 42.07 | 44.05 |
| Depreciation | 98.29 | 102 | 106 | 108 | 106 | 110 | 117 | 120 | 121 | 122 | 124 | 127 |
| Profit before tax | 34.87 | 107 | 17.94 | 22.92 | 131 | 311 | 223 | 269 | 326 | 360 | 479 | 590 |
| Tax % | 26.9% | 29.9% | 33.9% | 22.0% | 30.9% | 24.9% | 27.9% | 27.9% | 21.9% | 22.0% | 24.9% | 25.9% |
| Net Profit | 23.01 | 75.04 | 13.01 | 20.01 | 92.93 | 233 | 162 | 194 | 252 | 282 | 362 | 436 |
| EPS (Rs) | 0.44 | 1.41 | 0.24 | 0.38 | 1.72 | 4.34 | 3.03 | 3.62 | 4.68 | 5.19 | 6.82 | 8.20 |
| Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,772 | 1,898 | 2,050 | 2,285 | 2,822 | 4,799 | 4,924 | 6,020 | 5,027 | 5,542 | 6,795 | 7,798 |
| Expenses | 1,410 | 1,492 | 1,637 | 1,927 | 2,257 | 3,250 | 3,501 | 4,432 | 4,249 | 4,484 | 5,014 | 5,422 |
| Operating Profit | 362 | 408 | 414 | 357 | 565 | 1,553 | 1,425 | 1,593 | 780 | 1,056 | 1,787 | 2,382 |
| OPM % | 20.1% | 21.0% | 20.1% | 16.1% | 20.0% | 32.0% | 29.1% | 26.0% | 15.0% | 19.1% | 26.1% | 30.6% |
| Other Income | 3.99 | 31.92 | 28.92 | 14.95 | 4.99 | 22.91 | 13.95 | 5.98 | 23.92 | 74.73 | 46.85 | 39.87 |
| Interest | 111 | 100 | 80.15 | 88.08 | 90.07 | 68.09 | 102 | 165 | 183 | 216 | 171 | 165 |
| Depreciation | 86.25 | 106 | 125 | 164 | 187 | 206 | 252 | 325 | 386 | 431 | 482 | 495 |
| Profit before tax | 168 | 233 | 236 | 120 | 293 | 1,296 | 1,080 | 1,105 | 235 | 482 | 1,179 | 1,755 |
| Tax % | 21.0% | 18.9% | 28.9% | 22.0% | 12.9% | 24.0% | 23.0% | 27.9% | 28.9% | 26.9% | 25.0% | — |
| Exceptional items | 0.00 | 0.00 | 0.00 | −0.99 | −0.99 | 0.00 | −0.99 | 0.00 | −0.99 | 75.85 | −5.99 | — |
| Net Profit | 134 | 190 | 168 | 93.92 | 255 | 984 | 832 | 793 | 162 | 358 | 890 | 1,332 |
| EPS (Rs) | 4.26 | 3.61 | 3.17 | 1.77 | 4.79 | 18.39 | 15.45 | 14.71 | 2.99 | 6.66 | 16.52 | 24.89 |
| Dividend payout % | 2.0% | 8.0% | 9.1% | 17.1% | 10.1% | 11.1% | 13.1% | 14.1% | 27.1% | 18.1% | 12.1% | — |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16.03 | 16.01 | 106 | 106 | 106 | 107 | 107 | 107 | 108 | 108 | 108 | 108 |
| Reserves | 639 | 772 | 1,223 | 1,375 | 1,450 | 1,660 | 2,487 | 3,241 | 3,928 | 4,000 | 4,360 | 5,191 |
| Borrowings | 888 | 1,094 | 843 | 980 | 1,037 | 1,078 | 1,484 | 1,779 | 2,018 | 2,580 | 2,770 | 2,520 |
| Other Liabilities | 343 | 337 | 479 | 551 | 733 | 897 | 1,663 | 1,835 | 1,602 | 1,691 | 2,089 | 2,680 |
| Total Liabilities | 1,885 | 2,220 | 2,650 | 3,012 | 3,327 | 3,743 | 5,743 | 6,962 | 7,655 | 8,379 | 9,327 | 10,499 |
| Fixed Assets | 799 | 1,018 | 1,227 | 1,476 | 1,625 | 1,720 | 2,164 | 2,646 | 3,402 | 3,880 | 4,113 | 4,358 |
| CWIP | 110 | 70.24 | 143 | 164 | 110 | 67.20 | 363 | 815 | 553 | 424 | 459 | 775 |
| Investments | 6.99 | 6.99 | 2.99 | 2.99 | 2.99 | 2.99 | 2.99 | 30.98 | 49.90 | 124 | 233 | 309 |
| Other Assets | 969 | 1,125 | 1,277 | 1,369 | 1,589 | 1,951 | 3,212 | 3,470 | 3,652 | 3,951 | 4,522 | 5,058 |
| Inventories | 475 | 485 | 507 | 583 | 680 | 902 | 1,569 | 1,754 | 1,680 | 1,837 | 1,931 | 2,335 |
| Trade receivables | 284 | 443 | 566 | 569 | 707 | 789 | 1,302 | 1,349 | 1,574 | 1,658 | 2,002 | 2,147 |
| Cash & equivalents | 58.90 | 28.94 | 3.99 | 2.99 | 2.99 | 1.99 | 47.89 | 75.91 | 47.92 | 142 | 144 | 114 |
| Total Assets | 1,885 | 2,220 | 2,650 | 3,012 | 3,327 | 3,743 | 5,743 | 6,962 | 7,655 | 8,379 | 9,327 | 10,499 |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operating activity | −65.11 | 182 | 333 | 343 | 299 | 348 | 735 | 913 | 996 | 668 | 603 | 1,629 |
| Cash from investing activity | −398 | −313 | −290 | −385 | −253 | −221 | −942 | −915 | −999 | −824 | −682 | −1,088 |
| Cash from financing activity | 486 | 103 | −54.05 | 42.04 | −45.07 | −128 | 255 | 30.05 | −27.04 | 250 | 39.02 | −526 |
| Net cash flow | 23.96 | −26.98 | −9.99 | 0.99 | 0.00 | −0.99 | 46.96 | 26.97 | −29.97 | 92.85 | −38.95 | 12.99 |
| Capex | 382 | 326 | 277 | 390 | 253 | 221 | 687 | 875 | 987 | 676 | 639 | 1,067 |
| Free cash flow | −447 | −144 | 54.96 | −49.02 | 43.96 | 125 | 49.01 | 33.98 | 5.99 | −10.01 | 60.99 | 560 |
| CFO / OP % | −24.0% | 59.1% | 94.1% | 98.1% | 91.1% | 68.1% | 62.1% | 77.0% | 80.1% | 99.1% | 70.1% | 107.0% |
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor days | 79 | 92 | 110 | 102 | 114 | 103 | 100 | 101 | 97 | 121 | 133 | 116 |
| Inventory days | 210 | 176 | 186 | 201 | 201 | 234 | 266 | 293 | 222 | 277 | 285 | 317 |
| Days payable | 103 | 91 | 97 | 108 | 145 | 160 | 200 | 147 | 95 | 159 | 142 | 171 |
| Cash conversion cycle | 186 | 178 | 199 | 195 | 170 | 177 | 166 | 247 | 224 | 240 | 276 | 263 |
| Working capital days | 0 | 19 | 3 | −11 | 6 | 15 | 43 | 43 | 59 | 42 | 43 | 58 |
| ROCE % | 14.0% | 16.0% | 16.0% | 14.0% | 8.0% | 14.0% | 40.0% | 26.0% | 23.0% | 7.0% | 9.0% | 18.0% |
For the Sep 2026 quarter, Laurus Labs reported sales of ₹2,198 Cr, up 33.3% year on year and net profit of ₹436 Cr, up 124.7% year on year. The operating margin was 34.0%.
Laurus Labs' sales for the year to Mar 2026 were ₹6,795 Cr; over the last twelve months they were ₹7,798 Cr.
Net profit for the year to Mar 2026 was ₹890 Cr, and ₹1,332 Cr over the last twelve months. Earnings per share over the same trailing period were ₹24.89.
Laurus Labs reported borrowings of ₹2,520 Cr at Mar 2026, against cash and equivalents of ₹114 Cr.
Cash from operations was ₹1,629 Cr in the year to Mar 2026; after capital spending, free cash flow was ₹560 Cr.